For example, research using the CRISPR-dCas9 screening approach in bladder cancer has indicated the beneficial effects of a combination of CDK4/6 inhibitors with some inhibitors against PI3K-Akt, Ras/MAPK, JAK/STAT, or Wnt signaling pathways in bladder cancer therapy (31). This evidence concerns the gene CDK4 and urinary bladder carcinoma.